Nurix Therapeutics, Inc. (NRIX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Nurix Therapeutics, Inc. (NRIX) Healthcare & Pipeline Overview

Nurix Therapeutics, Inc. is a biopharmaceutical firm specializing in small molecule therapies targeting cancer and immune disorders, leveraging BTK degradation and CBL-B inhibition. Their pipeline includes NX-2127, NX-5948, and NX-1607, with collaborations with Gilead Sciences and Sanofi S.A., positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for NRIX?

Nurix Therapeutics presents a compelling investment case driven by its innovative approach to drug development through targeted protein degradation and inhibition. The company's pipeline, featuring BTK degraders (NX-2127 and NX-5948) and CBL-B inhibitors (NX-1607 and NX-0255), addresses significant unmet needs in oncology and immunology. Strategic collaborations with Gilead Sciences and Sanofi S.A. provide validation and financial support. A key value driver is the potential clinical success of NX-2127 in relapsed or refractory B-cell malignancies and NX-5948 in autoimmune diseases. The ongoing Phase 1 trial of DeTIL-0255 for gynecologic cancers represents another potential catalyst. However, the company's negative profit margin of -411.4% and gross margin of -139.4% highlight the financial risks associated with biotechnology companies that are in the development stage. The high beta of 1.98 indicates significant volatility. Investors should closely monitor clinical trial results and regulatory milestones.

Based on FMP financials and quantitative analysis

NRIX Key Highlights

Market Cap of $2.77B reflects investor confidence in Nurix Therapeutics' pipeline and technology.

• Profit Margin of -411.4% indicates the company is currently investing heavily in research and development.
• Gross Margin of -139.4% suggests that the cost of goods or services exceeds revenue, typical for development-stage biopharmaceutical companies.
• Beta of 1.98 indicates higher volatility compared to the overall market.
• Strategic collaborations with Gilead Sciences, Inc. and Sanofi S.A. validate Nurix's technology and provide financial resources.

Who Are NRIX's Competitors?

NRIX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NRIX's Key Strengths?

Innovative technology platform for targeted protein degradation.

• Strong pipeline of drug candidates in oncology and immunology.
• Strategic collaborations with Gilead Sciences and Sanofi S.A.
• Experienced management team with expertise in drug development.

What Are NRIX's Weaknesses?

High operating expenses due to research and development activities.

• Dependence on clinical trial outcomes and regulatory approvals.
• Negative profit margin and gross margin.
• Limited commercialization experience.

What Could Drive NRIX Stock Higher?

Clinical trial results for NX-2127 in relapsed or refractory B-cell malignancies.

• Clinical trial results for NX-5948 in autoimmune diseases.
• Data readouts from the Phase 1 trial of DeTIL-0255 for gynecologic cancers.
• Advancement of NX-1607 into later-stage clinical development.
• Potential for new strategic collaborations and partnerships.

What Are the Key Risks for NRIX?

Negative return on equity (-76.1%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials or regulatory setbacks.
• Competition from other biotechnology and pharmaceutical companies.
• Patent challenges or loss of intellectual property protection.
• High operating expenses and negative profit margin.
• Dependence on external funding and partnerships.

What Are the Growth Opportunities for NRIX?

• Expansion of BTK Degrader Programs: Nurix's BTK degrader programs, NX-2127 and NX-5948, represent a significant growth opportunity. The market for BTK inhibitors in B-cell malignancies is substantial, with potential for expansion into autoimmune diseases. Successful clinical trials and regulatory approvals could drive significant revenue growth. The timeline for commercialization depends on clinical trial progress, with potential for market entry within the next 3-5 years. The competitive advantage lies in the potential for improved efficacy and safety compared to existing BTK inhibitors.
• Advancement of CBL-B Inhibitor Programs: The development of CBL-B inhibitors, such as NX-1607 and NX-0255, offers another growth avenue. CBL-B inhibition has shown promise in enhancing anti-tumor immunity. The immuno-oncology market is rapidly expanding, with a growing demand for novel therapies. Clinical trials are underway to evaluate the efficacy of these inhibitors, with potential for commercialization in the next 4-6 years. Nurix's expertise in protein degradation provides a competitive edge in this area.
• Strategic Collaborations and Partnerships: Nurix's collaborations with Gilead Sciences and Sanofi S.A. provide access to resources and expertise, accelerating the development of its pipeline. Further strategic partnerships could expand the company's reach and diversify its portfolio. These collaborations can provide non-dilutive funding and access to new technologies. The timeline for realizing the benefits of these partnerships is ongoing, with potential for new collaborations in the future. The ability to attract and maintain these partnerships is a key competitive advantage.
• Clinical Development of DeTIL-0255: The Phase 1 clinical trial of DeTIL-0255 for gynecologic cancers represents a near-term growth opportunity. Positive clinical data could lead to accelerated regulatory approval and commercialization. The market for gynecologic cancer therapies is substantial, with significant unmet needs. The timeline for potential market entry is within the next 3-4 years, contingent on clinical trial success. The competitive advantage lies in the potential for improved outcomes compared to existing therapies.
• Expansion into New Therapeutic Areas: Nurix could leverage its expertise in protein degradation and inhibition to expand into new therapeutic areas beyond oncology and immunology. This could include neurodegenerative diseases, metabolic disorders, and other areas with significant unmet needs. The market for these therapies is vast, with potential for long-term growth. The timeline for expansion into new areas is dependent on research and development efforts, with potential for new programs in the next 5-7 years. The competitive advantage lies in the company's platform technology and expertise in drug discovery.

What Are NRIX's Competitive Advantages?

• Proprietary technology platform for targeted protein degradation.
• Strong intellectual property portfolio protecting its drug candidates.
• Strategic collaborations with leading pharmaceutical companies.

What Does NRIX Do?

Nurix Therapeutics, Inc., founded in 2009 and headquartered in San Francisco, California, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative small molecule therapies. These therapies are designed to address the unmet medical needs of patients suffering from cancer and immune disorders. The company's research focuses on modulating cellular protein levels through targeted protein degradation and inhibition. Nurix's pipeline features several promising drug candidates, including NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader, intended for the treatment of relapsed or refractory B-cell malignancies. Another key asset is NX-5948, an orally bioavailable BTK degrader being developed for both B-cell malignancies and autoimmune diseases. NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, is also under development for immuno-oncology indications. Additionally, Nurix is advancing NX-0255, a CBL-B inhibitor for ex vivo use in adoptive T-cell therapy, and DeTIL-0255, currently in Phase 1 clinical trials for gynecologic cancers such as ovarian, endometrial, and cervical cancer. Nurix Therapeutics collaborates with Gilead Sciences, Inc. and Sanofi S.A. to accelerate the development of its therapies. Formerly known as Nurix Inc., the company rebranded as Nurix Therapeutics, Inc. in October 2018, reflecting its commitment to innovative therapeutic solutions.

What Products and Services Does NRIX Offer?

• Discovers and develops small molecule therapies.
• Focuses on treatments for cancer and immune disorders.
• Develops Bruton's tyrosine kinase (BTK) degraders.
• Develops Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitors.
• Conducts clinical trials to evaluate drug candidates.
• Collaborates with pharmaceutical companies for research and development.

How Does NRIX Make Money?

• Develops and patents novel small molecule therapies.
• Out-licenses or co-develops therapies with larger pharmaceutical companies.
• Generates revenue through milestone payments and royalties from partnered programs.

What Industry Does NRIX Operate In?

Nurix Therapeutics operates within the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The market for cancer and immune disorder therapies is substantial and growing, driven by an aging population and increased disease prevalence. Companies like Nurix are focusing on novel approaches such as targeted protein degradation to differentiate themselves. The industry is marked by intense competition, with companies like TNGX: Tango Therapeutics, Inc. also pursuing innovative cancer therapies. Success depends on clinical trial outcomes, regulatory approvals, and effective commercialization strategies.

Who Are NRIX's Key Customers?

• Patients with cancer and immune disorders.
• Pharmaceutical companies through collaboration agreements.
• Healthcare providers who prescribe Nurix's therapies.

Nurix Therapeutics, Inc. Financial Trajectory

Nurix Therapeutics, Inc. (NRIX) reported $9.0M in revenue for Q2 2026, reflecting 44.6% growth compared to the prior quarter. The company recorded a net loss of $89.5M, with diluted EPS of $-0.81. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, NRIX averaged $-0.86 in diluted EPS.

Company Profile

Nurix Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO Arthur T. Sands. NRIX has traded publicly since 2020.

How Nurix Therapeutics, Inc. Is Valued

Nurix Therapeutics, Inc. carries a market capitalization of $2.77B, placing it in the mid-cap category. Relative to its peer group, NRIX's quantitative score of 19/100 is below the peer average of 82/100.

Return on equity for Nurix Therapeutics, Inc. stands at -76.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -63.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -11.5%, the inverse of the P/E and a quick read on earnings relative to price.

Nurix Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 8.41 places it in the safe zone, indicating low near-term bankruptcy risk.

Nurix Therapeutics, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 1.8% below estimates on average.

Wall Street analysts project Nurix Therapeutics, Inc. revenue of about $63.7M for fiscal 2026, with EPS near $-2.69. The estimate reflects 5 contributing analysts.

NRIX Financials

NRIX Latest News

NRIX Analyst Consensus

NRIX MoonshotScore

Nurix Therapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources